

# Genzyme in Multiple Sclerosis

## Patient-centric philosophy

Patient commitment is the cornerstone of Genzyme's legacy that spans more than 30 years of pioneering discovery and development of transformative therapies for patients affected by rare and debilitating diseases.

Our focus in MS is to deliver a new generation of therapies that address critical unmet treatment needs and establish collaborative partnerships and unique programs that provide positive, tangible benefits for the healthcare communities we serve globally.

Each person's experience with MS is unique. Genzyme's patient-centric philosophy drives our goals of improving patient outcomes on important clinical measures in MS disease, as well as to address quality-of-life concerns, such as convenience and tolerability. Genzyme is committed to partnering across the spectrum of care with patients and caregivers, advocacy organizations and foundations, as well as healthcare providers and payers.



## Breaking new ground

We embrace innovation at Genzyme and push ourselves to exceed expectations across our MS franchise to bring forward important new treatment options and break new ground with customized programs and services that are anything but standard.



For over a decade, Genzyme and Sanofi have worked to develop treatments for MS that address unmet needs. Integrated within Genzyme, our robust MS program includes the complementary therapies AUBAGIO® (teriflunomide), approved for use in 2012 in the U.S. and Australia, and LEMTRADA™ (alemtuzumab), both currently under review by regulatory agencies around the world.

Genzyme continues to innovate in MS treatment beyond AUBAGIO and LEMTRADA. The company is committed to developing the next generation of therapeutics for relapsing and progressive MS, focusing on immunomodulation, remyelination and repair of the central nervous system. We are partnering externally with leading

scientists, academic institutions and biotech companies to help enable us to break new ground in our understanding and treatment of this disabling disease.

## Redefining expectations

Driven by a team of experienced MS professionals, Genzyme is committed to becoming a long-term and trusted partner to the MS community. We are putting patients first with customized programs designed to address individual circumstances. MS One to One™ is one example of our dedicated Genzyme support program. We hope to use our collective experience and evolve the approach to MS care to meet the requirements of today—while anticipating the needs of tomorrow.

